Cardiovascular Systems to Present PAD Data and Offer Educational Sessions at AMP Chicago 2013 Symposium

  Cardiovascular Systems to Present PAD Data and Offer Educational Sessions at
  AMP Chicago 2013 Symposium

Business Wire

ST. PAUL, Minn. & CHICAGO -- August 6, 2013

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company
developing and commercializing innovative interventional treatment systems for
vascular disease, will present data from its studies of peripheral arterial
disease (PAD), as well as offer educational sessions, at the upcoming AMP
(Amputation Prevention) Symposium in Chicago, August 8-10.

AMP Podium Presentations

CSI will present data about orbital atherectomy in the treatment of PAD during
the following podium presentations at AMP:

Thursday, Aug. 8

  *10:50 – 11 a.m., Dr. George L. Adams, Rex Healthcare and University of
    North Carolina Health Systems, Garner, N.C.: “Orbital Atherectomy ATK and
    BTK”
  *11 – 11:10 a.m., Dr. Jihad Mustapha, Metro Heart & Vascular, Wyoming,
    Mich.: Taped case presentation: “Orbital Atherectomy”
  *11:18 – 11:26 a.m., Dr. Raymond Dattilo, St. Francis Health Center,
    Manhattan, Kan.: “Distal Protection Devices: Are They Needed During
    Atherectomy Cases?”

Friday, Aug. 9

  *1:13 – 1:21 p.m., Dr. Jihad Mustapha: Tibiopedal Arterial Minimally
    Invasive (TAMI) Retrograde Revascularization – TAMI Technique

Saturday, Aug. 10

  *8:28 – 8:38 a.m., Dr. Raymond Dattilo: “The Wrath of Calcification in CLI
    Patients: How Does It Impact Diagnostic Modalities and Revascularization
    Options?”
  *11:34 – 11:40 a.m., Dr. George Adams: “Orbital Atherectomy in 6 Minutes”
  *1:44 – 1:51 p.m., Dr. Raymond Dattilo: “Is Calcium a Major Barrier for
    Drug Eluting Delivery and What Are the Solutions to Improve Drug
    Delivery?”

AMP Poster Sessions

The following posters will be featured at AMP, Thursday, Aug. 8, through
Saturday, Aug. 10, from 7:30 a.m. to 6 p.m.:

  *Dr. George L. Adams, Rex Healthcare, Raleigh, NC: “Orbital Atherectomy
    Outcomes of the Claudicant Patient Population within the CONFIRM Series”
  *Dr. Tony Das, Cardiology and Interventional Vascular Associates, Dallas,
    Texas: “Orbital Atherectomy Outcomes of the Critical Limb Ischemia Patient
    Population within the CONFIRM Series”
  *Dr. Michael Lee, UCLA Medical Center, Los Angeles, Calif.: “Pooled
    Analysis of the CONFIRM Registries: Outcomes in Patients with Renal
    Disease Treated for Peripheral Arterial Disease with Orbital Atherectomy”
    and “Pooled Analysis of the CONFIRM Registries: Impact of Gender on
    Outcomes in Patients Treated for Peripheral Arterial Disease with Orbital
    Atherectomy”


Atherectomy Workshop and Cadaver Summit: Aug. 8

WHAT: CSI has provided an educational grant for a roundtable atherectomy
workshop and cadaver course at AMP, featuring ultrasound guided tibial and
pedal access followed by orbital atherectomy treatment.


WHEN:   Thursday, Aug. 8, 1 – 5 p.m.

WHERE:   Roundtable Atherectomy Workshop
         Grand Ballroom
         Chicago Marriott Downtown – Magnificent Mile
         540 N. Michigan Ave.
         Chicago, IL

         Atherectomy Summit Cadaver Course
         6^th Floor Indiana, Iowa, Michigan and Michigan State Rooms
         Chicago Marriott Downtown – Magnificent Mile
         540 N. Michigan Ave.
         Chicago, IL
         


Lunch Symposium: Aug. 8

WHAT: Leading PAD physicians will share their expertise during a lunch
symposium at AMP. The symposium will cover the many costs of calcium and the
usage of orbital atherectomy for plaque modification, as well as successful
treatment case studies, and more.


WHEN:      Thursday, Aug. 8, 11:50 a.m. – 12:50 p.m.

WHERE:      Grand Ballroom
            Chicago Marriott Downtown – Magnificent Mile
            540 N. Michigan Ave.
            Chicago, IL

SCHEDULE:   The Many Costs of Calcium, Dr. Lawrence Garcia, St. Elizabeth’s
            Medical Center, Boston, Mass.

            The Orbital Atherectomy Revolution, Dr. Robert Vorhies, Cox Health
            Systems, Springfield, Mo.

            The Orbital Evidence: Successful Orbital Atherectomy Treatment
            Case Studies, Dr. Jihad Mustapha

            Q & Atherectomy
            

CSI Booth at AMP: Aug. 9 – 10

Visit CSI at booth #409, 9:15 a.m. – 6:30 p.m. Friday, Aug. 9 and 9:30 a.m. –
3:30 p.m. Saturday, Aug. 10 to meet the company’s calcium experts and learn
more about CSI’s unique orbital technology.

About Peripheral Arterial Disease
As many as 8 million to 12 million Americans, most over age 65, suffer from
PAD, which is caused by the accumulation of plaque in peripheral arteries
(commonly the pelvis or leg) reducing blood flow. Symptoms include leg pain
when walking or at rest. Left untreated, PAD can lead to severe pain,
immobility, non-healing wounds and eventually limb amputation. With risk
factors such as diabetes and obesity on the rise, the prevalence of PAD is
growing faster than the rest of the population.

Millions of patients with PAD may benefit from treatment with orbital
atherectomy utilizing the Stealth 360° and Diamondback 360°, minimally
invasive catheter systems developed and manufactured by CSI. These systems use
a diamond-coated crown, attached to an orbiting shaft, which sands away plaque
while preserving healthy vessel tissue — a critical factor in preventing
reoccurrences. Balloon angioplasty and stents have significant shortcomings in
treating hard, calcified lesions. Stents are prone to fractures and high
recurrence rates, and treatment of hard, calcified lesions often leads to
vessel damage and suboptimal results.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the limitations
associated with existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of the
Diamondback Orbital Atherectomy System in August 2007. To date, nearly 110,000
of CSI’s devices have been sold to leading institutions across the United
States. CSI has also completed its ORBIT II Investigational Device Exemption
clinical trial to evaluate the safety and effectiveness of its orbital
technology in treating coronary arteries. The coronary system is limited by
federal law to investigational use and is currently not commercially available
in the United States.

For more information, visit the company’s website at www.csi360.com.

Contact:

For Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
investorrelations@csi360.com
or
Sarah Wozniak, 651-259-1636
swozniak@csi360.com
or
Padilla Speer Beardsley:
Matt Sullivan, 612-455-1709
msullivan@padillaspeer.com
or
Dave Folkens, 612-455-1741
dfolkens@padillaspeer.com